Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma

Table 3 Distribution of PIFR

	Patients using 2 or more inhalers (%)	Patients using 2 or more DPIs (%)	PIFR₀, L/min	PIFR_BT, L/min	PIFR_AT, L/min
All patients	61 (28.9)	27 (12.9)	118.0 (90.0,120.0)	55.4 ± 21.1	61.0 ± 18.8
Asthma/COPD group
Asthma group	14 (15.1)	5 (5.4)	120.0 (90.0,120.0)	56.6 ± 20.6	62.9 ± 17.4
COPD group	47 (40.2)	22 (18.8)	115.0 (85.0,120.0)	54.7 ± 21.5	60.0 ± 17.8
P value (MD, 95%CI)	/	/	0.445	0.541 (MD = 1.9, 95% CI [−4.3, 8.1])	0.278 ((MD = 3.2, 95% CI [−2.6, 8.9])
ND/FU group
ND group	10 (13.0)	5 (6.4)	105.0 (70.0, 120.0)	47.8 ± 18.0	55.9 ± 16.1
FU group	51 (38.3)	22 (16.6)	120.0 (95.0, 120.0)	60.0 ± 21.6	64.0 ± 17.9
p value	/	/	0.000	0.000 (MD = 12.1, 95%CI [6.2,18,1])	0.002 (MD = 8.9, 95%CI [3.3,14.5])
AE/stable group
AE group	19 (54.3)	8 (22.9)	120.0 (90.0, 120.0)	51.3 ± 18.5	51.8 ± 11.4
Stable group	42 (24.1)	19 (10.9)	110.0 (77.5, 120.0)	56.5 ± 21.5	63.3 ± 17.9
p value	/	/	0.143	0.192 (MD = 5.2, 95% CI [−2.6,13.0])	0.000 (MD = 13.0, 95% CI [−5.9, 20.1])

Patients using 2 or more inhalers/DPIs are shown as number (%) patients. Data are shown as means ± standard deviation or median (25% quartile, 75%quartile). The PIFR data in Table 3 includes PIFR₀ of all patients, and PIFR_BT and PIFR_AT only for patients using DPIs
CI, confidence interval; COPD, chronic obstructive pulmonary disease; AE, acute exacerbation; ND, newly-diagnosed; FU, follow-up; PIFR₀, peak inhalation flow rate measured at resistant of “pMDI”; PIFR_BT, peak inhalation flow rate measured before-training; PIFR_AT, peak inhalation flow rate measured after training; MD, mean difference

ISSN: 1471-2466